STOCKHOLM The two researchers, from Japan and the U.S., who won the Nobel Prize in medicine on Monday are credited for discoveries that have revolutionized cancer care, turning the bodys immune system loose to fight tumors.
James Allison of the University of Texas M.D. Anderson Cancer Center and Tasuku Honjo of Kyoto University learned how cancer can put the brakes on the immune system and how to release those brakes.
Their work, conducted separately during the 1990s, led to the development of drugs known as checkpoint inhibitors, first used to treat the deadly skin cancer melanoma but now used for a growing list of advanced-stage tumors, including those of the lungs, head and neck, bladder, kidney, colon and liver.
The drugs marked an entirely new way to treat tumors, a kind of immunotherapy that uses the patients own body to kill cancer cells. Up until then, the standard arsenal consisted of surgery to remove the tumor and radiation and chemotherapy to poison the cancer.
The research was a landmark in our fight against cancer, the Nobel Assembly of Swedens Karolinska Institute said in announcing the award.
Not all patients respond to this, but for the ones that do, it has made a huge difference to their lives, said Dr. Arlene Sharpe, co-chair of microbiology and immunobiology at Harvard Medical School. There are patients over a decade ago who had an incredibly poor prognosis and now, a decade out, they are living normal lives.
Dr. Jedd Wolchok, chief of the melanoma and immunotherapeutics service at Memorial Sloan Kettering Cancer Center in New York, said, An untold number of lives have been saved by the science that they pioneered.
Indeed, a drug based on Honjos research was used to treat former President Jimmy Carter, who was diagnosed in 2015 with melanoma that had spread to his brain. A year later, he announced he no longer needed treatment.
Allison, 70, who was at a New York hotel for a scientific meeting, said at a news conference that the Nobel committee evidently had trouble reaching him to break the news. But his cellphone lit up with a call from his son at 5:30 a.m., when the names of the winners were released.
And soon, there were people beating on my door at 6 in the morning with Champagne, he said.
At a news conference in Kyoto, Honjo, 76, told how a member of his golf club once walked up to thank him for the discovery that was used to treat his lung cancer.
He told me, Thanks to you I can play golf again, he recalled. That was a blissful moment. A comment like that makes me happier than any prize.
Scientists had been trying for a century to harness the immune system against cancer, but it was a struggle. Normally, key immune system soldiers called T cells seek out and attack invaders. But for poorly understood reasons, it was hard to rev them up against cancer.
In an interview Monday, Allison said he wasnt trying to cure cancer but to understand how T cells work when, at the University of California, Berkeley, he was studying a protein named CTLA-4. He learned that the protein could put the brakes on T cells, creating whats called an immune checkpoint.
He then created an antibody that blocked the proteins action in other words, it released the brakes so the T cells could do their job.
Working separately, Honjo discovered another protein, called PD-1, that also hampers T cells ability to attack cancer, but in a somewhat different way.
Allisons research led to development of the drug Yervoy, approved in 2011 after studies showed it extended the survival of some patients with late-stage melanoma. A few years later, developers created drugs that release the PD-1 brake Honjo discovered Keytruda and Opdivo, now commonly advertised on TV.
Allison said the biggest challenge with immunotherapy now is to learn why it helps some patients but not others and how to combine it with traditional therapies to improve outcomes and reduce side effects.
Its a great emotional privilege to meet cancer patients whove been successfully treated with immune checkpoint blockade. They are living proof of the power of basic science, he said in a statement.
Be Part of Quality Journalism
Quality journalism takes a lot of time, money and hard work to produce and despite all the hardships we still do it. Our reporters and editors are working overtime in Kashmir and beyond to cover what you care about, break big stories, and expose injustices that can change lives. Today more people are reading Kashmir Observer than ever, but only a handful are paying while advertising revenues are falling fast.